FDA approves expanded use of AstraZeneca ovarian cancer drug
August 17, 2017 at 16:35 PM EDT
Aug 17 (Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.